Research graph
References from Sequencing immunotherapy in locally advanced head and neck squamous cell carcinoma: a narrative clinical-translational review. Local targets link to admitted publications; unresolved targets remain external evidence.
Meta-analysis of chemotherapy in head and neck cancer (Mach-Nc): An update on 107 randomized trials and 19,805 patients, on behalf of Mach-Nc group
10.1016/j.radonc.2021.01.013 · 2021 · External reference
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (Hnscc): A meta-analysis of randomized trials
10.1016/j.radonc.2015.10.014 · 2016 · External reference
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (Keynote-048): A randomised, open-label, phase 3 study
10.1016/s0140-6736(19)32591-7 · 2019 · External reference
Radiation as an immune modulator: Mechanisms and implications for combination with immunotherapy
10.1038/s41568-025-00903-x · 2026 · External reference
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (Keynote-412): A randomised, double-blind, phase 3 trial
10.1016/s1470-2045(24)00100-1 · 2024 · External reference
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
10.1016/s1470-2045(20)30737-3 · 2021 · External reference
Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer
10.1056/nejmoa2415434 · 2025 · External reference
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (Gortec 2018-01 Nivopost-Op): A randomised, open-label, phase 3 trial
10.1016/s0140-6736(25)01850-1 · 2026 · External reference
Avelumab-cetuximab-radiotherapy (Rt) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (La-Scchn): Final analysis of randomized phase Iii Gortec 2017-01 Reach trial
10.1016/j.annonc.2024.08.915 · 2024 · External reference
Long-term results of the randomized, phase 3 Keynote-412 trial of pembrolizumab (Pembro) or placebo (Pbo) plus concurrent chemoradiotherapy (Crt) for unresected, locally advanced head and neck squamous cell carcinoma (La Hnscc)
10.1200/jco.2025.43.16_suppl.6013 · 2025 · External reference
Avelumab, an Igg1 anti-Pd-L1 immune checkpoint inhibitor, triggers Nk cell-mediated cytotoxicity and cytokine production against triple-negative breast cancer cells
10.3389/fimmu.2018.02140 · 2018 · External reference
Atezolizumab in high-risk locally advanced squamous cell carcinoma of the head and neck: A randomized clinical trial
10.1001/jama.2025.1483 · 2025 · External reference
Perioperative Camrelizumab plus chemotherapy in locally advanced squamous cell carcinoma of the head and neck (Camoral): A multicenter, open-label, randomized phase Ii study
10.1016/j.annonc.2025.08.1951 · 2025 · External reference
Randomized phase Ii study of concurrent versus sequential pembrolizumab in combination with chemoradiation in locally advanced head and neck cancer
10.1200/jco-24-01580 · 2025 · External reference
Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors
10.1038/s41467-022-34676-w · 2022 · External reference
Pd-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
10.1038/nature22396 · 2017 · External reference
Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease
10.1038/s41467-024-49873-y · 2024 · External reference
The tumor-sentinel lymph node immuno-migratome reveals Ccr7+ dendritic cells drive response to sequenced immunoradiotherapy
10.1038/s41467-025-61780-4 · 2025 · External reference
Survival and human papillomavirus in oropharynx cancer in Tax 324: A subset analysis from an international phase Iii trial
10.1093/annonc/mdr006 · 2011 · External reference
Results from Compare phase Iii Rct: Neoadjuvant durvalumab plus chemoradiotherapy (Crt) followed by adjuvant durvalumab immunotherapy (Io) vs Crt alone in intermediate and high-risk oropharyngeal cancer (Opc)
10.1016/j.annonc.2025.08.1949 · 2025 · External reference
Comparison of Pd-L1 expression in head and neck squamous cell carcinoma among preoperative biopsy, surgical resection and metastatic lymph node
10.3389/fonc.2025.1666078 · 2025 · External reference
Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage Iii non–small cell lung cancer: The phase Iii Pacific-2 study
10.1200/jco-25-00036 · 2025 · External reference
Concurrent chemoradiation +/-Atezolizumab (Atezo) in limited-stage small cell lung cancer (Ls-Sclc): Results of Nrg Oncology/Alliance Lu005
10.1016/j.ijrobp.2024.08.013 · 2024 · External reference
Durvalumab after chemoradiotherapy in stage Iii non-small-cell lung cancer
10.1056/nejmoa1709937 · 2017 · External reference
Five-year survival outcomes from the Pacific trial: Durvalumab after chemoradiotherapy in stage Iii non-small-cell lung cancer
10.1200/jco.21.01308 · 2022 · External reference
Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer
10.1056/nejmoa2404873 · 2024 · External reference
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer
10.1056/nejmoa2032125 · 2021 · External reference
